- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 43 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen | |
| 14.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2025 | 157 | GlobeNewswire (Europe) | January-March 2025• Net sales, which for the quarter only included royalties, amounted to 139 KSEK (156).• Net earnings were -57.8 MSEK (-2.9), as a result of unrealized exchange rate effects due to... ► Artikel lesen | |
| 02.04. | IMMUNOVIA AB: Immunovia publishes the Annual Report for 2024 | 1 | Cision News | ||
| 01.04. | IMMUNOVIA AB: The exercise period for warrants series TO 3 begins today | 2 | Cision News | ||
| 27.03. | IMMUNOVIA AB: Immunovia announces determined exercise price for warrants series TO 3 | 2 | Cision News | ||
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 194 | PR Newswire | LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 24.03. | Immunovia AB: Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test | 170 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic... ► Artikel lesen | |
| 21.03. | IMMUNOVIA AB: Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study | 2 | Cision News | ||
| 19.03. | Immunovia AB: Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test | 157 | GlobeNewswire (Europe) | LUND (SWEDEN) - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation... ► Artikel lesen | |
| 03.03. | IMMUNOVIA AB: Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference | 1 | Cision News | ||
| 25.02. | Immunovia reports Q4 results | 2 | Seeking Alpha | ||
| 25.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2024 | 202 | PR Newswire | LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October- December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
... ► Artikel lesen | |
| 31.01. | Change in number of shares and votes in Immunovia AB (publ) | 279 | PR Newswire | LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series... ► Artikel lesen | |
| 20.01. | Immunovia AB announces outcome of exercise of warrants series TO 2 | 354 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
| 08.01. | Immunovia AB (Publ) presents Nomination Committee | 279 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
| 02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 372 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
| 28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 893 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen | |
| 19.12.24 | Immunovia AB: End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding | 190 | PR Newswire | LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities... ► Artikel lesen | |
| 09.12.24 | Immunovia AB: Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer | 146 | PR Newswire | LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the... ► Artikel lesen | |
| 27.11.24 | Immunovia AB: Immunovia Publishes Interim Report for January-September 2024 | 298 | PR Newswire | LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --
July-September 2024
Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 6,150 | -0,68 % | 780 % Rendite dank teurer Medizin: PanGenomic Health, CVS Health, Teladoc Health | Die Kosten im Gesundheitswesen explodieren. Wie KFF, eine führende gesundheitspolitische Organisation der USA schreibt, gaben die Vereinigten Staaten bereits 2022 rund 4,5 Billionen USD für Gesundheit... ► Artikel lesen | |
| HIMS & HERS HEALTH | 37,320 | +0,16 % | Verkaufswelle: Abo-Falle? FTC bohrt bei Hims & Hers nach - Anleger fliehen! | © Foto: Thomas Fuller - SOPA Images via ZUMA Press WireNach einem Bericht über eine laufende FTC-Untersuchung ist die Aktie des Telemedizin-Anbieters von Hims & Hers im nachbörslichen Handel deutlich... ► Artikel lesen | |
| BECTON DICKINSON | 171,10 | +0,06 % | Aktienmarkt: Starke Nachfrage treibt Kurs der Aktie von Becton Dickinson (159,35 €) | Die Aktie von Becton Dickinson zählt heute zu den großen Gewinnern am Aktienmarkt. Der Kurs der Aktie legt kräftig zu. Zu den Gewinnern an der Börse zählt aktuell das Wertpapier von Becton Dickinson.... ► Artikel lesen | |
| DEXCOM | 69,52 | -0,81 % | Dexcom-Aktie: Kurs mit wenig Bewegung (69,2637 €) | Die Wertschätzung für den Anteilsschein von Dexcom hat sich am Aktienmarkt heute kaum geändert. Das Wertpapier kostete zuletzt 80,67 US-Dollar. Die Wertschätzung der Investoren für das Wertpapier von... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,641 | +0,63 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update | FDA Provides Positive Feedback, Clears Path for Atossa to File IND for (Z)-Endoxifen in Metastatic Breast Cancer; FDA Indicates No Additional Toxicity Studies Required
Strong... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update | -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter --
-- Evofem Advances Plans for Special Meeting of Stockholders to Approve... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,154 | -2,20 % | XFRA AUFHEBUNG VON AMTS WEGEN IN NZRYME0001S4 | Folgende Geschaefte in der ISIN NZRYME0001S4, Wertpapier-Name: RYMAN HEALTHCARE GRP LTD, wurden von Amts wegen aufgehoben:Datum Zeit Volumen Preis24.02.2025 08:02:33 100 2.388 ► Artikel lesen | |
| CYTOSORBENTS | 0,790 | +0,89 % | CytoSorbents Corporation: CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR | FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
| SENSEONICS | 0,383 | +2,57 % | Senseonics Holdings, Inc. Reports Second Quarter Financial Results | Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| STAAR SURGICAL | 23,870 | -0,54 % | Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical | Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted... ► Artikel lesen | |
| EKSO BIONICS | 3,275 | +5,65 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| SOLENO THERAPEUTICS | 57,65 | -2,54 % | BREAKING: Soleno Therapeutics nach Short-Report massiv unter Beschuss | "Der größte reine Biotech-Betrug in den USA gemessen an der Marktkapitalisierung", hat Scorpion Capital vor Kurzem auf der Kurznachrichtenplattform X geschrieben. Der aktivistische Leerverkäufer knöpft... ► Artikel lesen | |
| INSPIRE MEDICAL SYSTEMS | 77,78 | -2,60 % | 13 Analysts Have This To Say About Inspire Medical Systems | ||
| INTERPACE BIOSCIENCES | 0,915 | +12,27 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk | Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace"... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,047 (+68,42 %) liegt der Kurs bei 0,115 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.